drugset / Trial / NCT02957474

A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects

NCT02957474 ↗

Phase 1 Completed 18 enrolled Celgene Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

This is an open label, single-center, 4-period, 6-sequence study in healthy subjects to compare the PK of GED 0301 after a single oral dose in the fed and fasted state, and after co administration with omeprazole, a proton pump inhibitor. The study will consist of a screening phase, a baseline phase, four treatment periods, and a follow up phone call five days (± 1 day) after discharge.

Timeline

Start
2016-11
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MONGERSEN SODIUM Antisense oligonucleotide 160 mg Oral
Subject Omeprazole Other / unclassified 40 mg Oral

Indications

No indication recorded.